These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 18336314)

  • 1. Carbonic anhydrase inhibition: insight into non-COX-2 pharmacological effect of some coxibs.
    Dogné JM; Thiry A; Supuran CT
    Curr Pharm Des; 2008; 14(7):679-84. PubMed ID: 18336314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual Human Carbonic Anhydrase/Cyclooxygenase-2 Inhibitors: A Promising Approach for Cancer Treatment.
    Mahboubi-Rabbani M; Zarghi A
    Anticancer Agents Med Chem; 2021 Oct; 21(16):2163-2180. PubMed ID: 33511940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COXIBs, CINODs and H₂S-releasing NSAIDs: current perspectives in the development of safer non steroidal anti-inflammatory drugs.
    Fiorucci S; Distrutti E
    Curr Med Chem; 2011; 18(23):3494-505. PubMed ID: 21756233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Cyclooxygenase and Carbonic Anhydrase Inhibition by Nonsteroidal Anti-Inflammatory Drugs for the Treatment of Cancer.
    De Monte C; Carradori S; Gentili A; Mollica A; Trisciuoglio D; Supuran CT
    Curr Med Chem; 2015; 22(24):2812-8. PubMed ID: 26180003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal safety of novel nonsteroidal antiinflammatory drugs: selective COX-2 inhibitors and beyond.
    Coruzzi G; Venturi N; Spaggiari S
    Acta Biomed; 2007 Aug; 78(2):96-110. PubMed ID: 17933277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.
    Martelli A; Testai L; Anzini M; Cappelli A; Di Capua A; Biava M; Poce G; Consalvi S; Giordani A; Caselli G; Rovati L; Ghelardini C; Patrignani P; Sautebin L; Breschi MC; Calderone V
    Pharmacol Res; 2013 Dec; 78():1-9. PubMed ID: 24083950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
    Weber A; Casini A; Heine A; Kuhn D; Supuran CT; Scozzafava A; Klebe G
    J Med Chem; 2004 Jan; 47(3):550-7. PubMed ID: 14736236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual carbonic anhydrase--cyclooxygenase-2 inhibitors.
    Dogné JM; Thiry A; Pratico D; Masereel B; Supuran CT
    Curr Top Med Chem; 2007; 7(9):885-91. PubMed ID: 17504133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The COXIB experience: a look in the rearview mirror.
    Marnett LJ
    Annu Rev Pharmacol Toxicol; 2009; 49():265-90. PubMed ID: 18851701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
    Tacconelli S; Bruno A; Grande R; Ballerini P; Patrignani P
    Expert Opin Drug Saf; 2017 Jul; 16(7):791-807. PubMed ID: 28569569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in COX-2 inhibitors: a journey so far.
    Chakraborti AK; Garg SK; Kumar R; Motiwala HF; Jadhavar PS
    Curr Med Chem; 2010; 17(15):1563-93. PubMed ID: 20166930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Is there a future for COX-2 inhibitors?].
    Yodfat Y
    Harefuah; 2004 Nov; 143(11):820-4, 837. PubMed ID: 15603272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR; Butler KA; Wallace RL; Smith SM; Harirforoosh S
    J Clin Pharm Ther; 2017 Feb; 42(1):27-38. PubMed ID: 28019014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risks.
    Cairns JA
    Can J Cardiol; 2007 Feb; 23(2):125-31. PubMed ID: 17311118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evidence-based evaluation of the gastrointestinal safety of coxibs.
    Bombardier C
    Am J Cardiol; 2002 Mar; 89(6A):3D-9D. PubMed ID: 11909555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2-selective inhibitors (COXIBs): gastrointestinal safety.
    Pronai L; Hritz I; Molnar B; Herszenyi L; Tulassay Z
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):23-30. PubMed ID: 14552701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The safety of COX-2 inhibitors].
    Lakatos G; Herszényi L; Tulassay Z
    Orv Hetil; 2008 Aug; 149(33):1539-47. PubMed ID: 18687572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives.
    Bruno A; Tacconelli S; Patrignani P
    Basic Clin Pharmacol Toxicol; 2014 Jan; 114(1):56-63. PubMed ID: 23953622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Management of Adverse Effects Associated with Nonsteroidal Anti-inflammatory Drugs and COX-2 Inhibitor].
    Masuda R
    Masui; 2016 Aug; 65(7):709-717. PubMed ID: 30358302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual acting anti-inflammatory drugs: a reappraisal.
    Bertolini A; Ottani A; Sandrini M
    Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.